Press releases & announcements
15 June, 2017
8 June, 2017
News from the Company 08-Jun-2017 RhoVac AB (“RhoVac”) today announced that a translation difference has been reported incorrectly in the company’s annual report. However, the error is not considered to... [Read more]
26 May, 2017
News from the Company 2017-05-26 RhoVac AB (“RhoVac”) today announced that the company is launching an English version of the company’s website. RhoVac is a biotechnology company, now in clinical... [Read more]
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.